Filing identity and reporting period
Important mismatch: The request identifies Viridian Therapeutics, Inc., but the supplied 10-Q is for Signal Genetics, Inc. This summary covers the supplied filing, not Viridian Therapeutics. The filing reports the unaudited quarter and six months ended June 30, 2014. Signal Genetics was a commercial-stage molecular diagnostics company whose revenue came primarily from its MyPRS multiple-myeloma test.
Financial results and liquidity
| Metric | Three months ended June 30, 2014 | Three months ended June 30, 2013 | Six months ended June 30, 2014 | Six months ended June 30, 2013 |
|---|---|---|---|---|
| Net revenue | $1.274 million | $1.103 million | $2.364 million | $2.242 million |
| Operating loss | $2.811 million | $60,373 | $2.978 million | $139,625 |
| Net loss attributable to stockholders | $3.289 million | $629,691 | $3.995 million | $1.257 million |
| Basic and diluted loss per share | $1.13 | $0.24 | $1.40 | $0.49 |
- Revenue increased 15.5% in the quarter and 5.4% for the six months. Gross margin, calculated as net revenue less cost of revenue, was approximately 46.9% for the quarter and 43.4% for the six months, versus approximately 45.3% and 43.3% in the comparable 2013 periods.
- Reported losses included $2.875 million of stock-based compensation associated mainly with IPO-related restricted stock unit awards. Interest expense was $1.017 million for the half year, mostly non-cash related-party interest accrued before the debt conversion.
- Cash was $7.696 million at June 30, 2014, versus $209,348 at December 31, 2013. Working capital was approximately $7.631 million; current liabilities were $2.137 million. Cash used in operations was $385,223 for the six months.
- The June IPO issued 850,000 shares at $10 per share, generating approximately $6.144 million net proceeds. Separately, $27.326 million of related-party debt was converted into equity. At June 30, the remaining $1.045 million due to a related party was non-interest-bearing and payable on demand; equipment-backed note debt was approximately $10,600.
- Total lease termination liability was approximately $431,000 at June 30. The company had $50,199 of restricted cash collateralizing a $50,000 standby letter of credit.
Material changes versus the prior comparable period
- Quarterly revenue grew despite fewer UAMS tests: 899 versus 936. Management attributed the UAMS revenue increase primarily to a 17% higher average selling price per test and changes in test and payor mix. Non-UAMS hospital revenue also increased.
- For the six months, UAMS test volume fell 11% (1,640 versus 1,846), while average selling price increased 15%. Non-UAMS hospital revenue rose, partly offset by the end of a pharmaceutical-company clinical study.
- Net losses widened substantially, principally because of IPO-related stock compensation and, for the half year, higher interest expense before the June debt conversion. Management expected interest expense to decrease significantly after the conversion.
- Revenue allowances rose to approximately 17% of gross revenue in 2014 from approximately 11% in 2013, which the company linked mainly to a lower share of direct-billed customer revenue.
- Days sales outstanding increased to 94 from 89 at year-end 2013, with management citing increased non-contracted payor receivables and slower collections.
Outlook, risks, and unusual items
- Management forecast continued losses and negative operating cash flows, but said cash on hand was expected to support operations at least through August 2015. It may seek additional financing or strategic investment; availability and terms are uncertain, and lack of funding could force spending reductions.
- Management planned to expand sales and marketing after the IPO and expected research and development spending to rise as it pursued additional tests and MyPRS indications. The filing gives no quantified revenue, earnings, or margin guidance.
- Key business risks include dependence on UAMS (about 81% of six-month 2014 revenue), uncertain insurance coverage and reimbursement, reliance on a single supplier for testing inventory, and dependence on its sole laboratory. The filing also highlights regulatory uncertainty over FDA oversight of laboratory-developed tests and the possibility of reduced Medicare or other payor reimbursement.
- Disclosure controls were deemed ineffective because of a material weakness tied to limited accounting and finance staffing and reliance on outside consultants. A new CFO with public-company reporting expertise took office August 4, 2014; remediation was planned but not assured.
- Other notable items: a CFO transition effective August 4; additional restricted stock unit and option awards granted in July and August; and a landlord lease-termination agreement requiring monthly payments through August 2015. The company reported no current lawsuits.
Most important facts for investors to verify
- Confirm the issuer: the supplied filing is Signal Genetics, Inc., not Viridian Therapeutics, Inc.
- Assess the sustainability and collectability of revenue, including UAMS concentration, non-contracted payor exposure, contractual allowance estimates, and aging receivables.
- Evaluate the stated cash runway against operating cash use, planned commercial and R&D spending, and the need for future financing.
- Review the material weakness and whether the new finance leadership remediated reporting-control deficiencies.
- Check the impact of reimbursement and FDA policy changes, supplier concentration, and the single-laboratory dependency.
- The cover page marks “No” for having filed all required reports during the preceding 12 months; verify the applicable reporting history and context.